SCHEMBL25754487

SCHEMBL25754487

CC#CC(O)C(N)COCCCCCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.51
USP2 O75604 1/20 0.49
SPHK1 Q9NYA1 2/20 0.47
LPAR5 Q9H1C0 4/20 0.42
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 1/20 0.39
LPAR1 Q92633 7/20 0.39
LPAR3 Q9UBY5 7/20 0.39
LPAR2 Q9HBW0 4/20 0.39
LPAR6 P43657 3/20 0.39
LPAR4 Q99677 3/20 0.39
CYP2D6 P10635 2/20 0.39
MAPT P10636 2/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
THPO P40225 1/20 0.39
MTOR P42345 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754480 0.87 HTT (0.40) HTTUSP2SPHK1CYP3A4
SCHEMBL25754490 0.85 HTT (0.34) HTTUSP2SPHK1
SCHEMBL25754488 0.83 HSD17B10 (0.42) HTTUSP2
SCHEMBL25754231 0.80 USP2 (0.55) HTTUSP2SPHK1LPAR5CYP1A2
SCHEMBL5798415 0.78 SPHK1 (0.59) HTTUSP2SPHK1LPAR5CYP1A2
SCHEMBL2728416 0.78 SPHK1 (0.59) HTTUSP2SPHK1LPAR5CYP1A2
SCHEMBL2727038 0.78 SPHK1 (0.59) HTTUSP2SPHK1LPAR5CYP1A2
SCHEMBL2728753 0.78 SPHK1 (0.59) HTTUSP2SPHK1LPAR5CYP1A2
SCHEMBL25754483 0.77
SCHEMBL25754243 0.77 USP2 (0.51) HTTUSP2SPHK1LPAR5CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 HTT 916/4885USP2 51/4885SPHK1 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.